Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

Cited by (239)

Items 101–200 of 239

1. Enantioselective synthesis of chiral γ-aryl α-keto ester by copper-catalyzed 1,4-conjugate addition using D2-symmetric biphenyl phosphoramidite ligand
   Bo Han Yang, Fang Xie, Han Yu, Kaiji Shen, Zhenni Ma, Wanbin Zhang · 2011 · Tetrahedron
2. Interleukin 6 polymorphism corresponds to the number of severely stenosed coronary arteries.
   Jolanta M. Myśliwska, Joanna Więckiewicz, Łukasz Hak, Janusz Siebert, Jan A. Rogowski, Krzysztof Szyndler, Andrzej Myśliwski · 2006 · PubMed
3. Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension
   Vanessa Fontana, Pamela S. Silva, Tatiane C. Izidoro‐Toledo, Celso Biagi, Eduardo Brandt Oliveira, Raquel F. Gerlach, José Eduardo Tanus-Santos · 2012 · Cardiovascular Drugs and Therapy
4. Effects of AT1 Receptor Antagonism With Candesartan on Endothelial Function in Patients With Hypertension and Coronary Artery Disease
   Pasquale Perrone Filardi, Luigi Corrado, Gregorio Brevetti, Antonio Silvestro, Santo Dellegrottaglie, Maria Cafiero, Gianluca Caiazzo, Andrea Petretta, Antonio Maglione, Cinzia Monda et al. · 2009 · Journal of Clinical Hypertension
5. Second World Congress on the Insulin Resistance Syndrome
   Zachary T. Bloomgarden · 2005 · Diabetes Care
6. Reduction of age-associated arterial wall changes by low-dose valsartan
   Mojca Lunder, Miodrag Janić, Mišo Šabović · 2011 · European Journal of Preventive Cardiology
7. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation
   Maren Luchtefeld, Nele Bandlow, Uwe J.F. Tietge, Karsten Grote, Josef M. Pfeilschifter, Marietta Kaszkin, Sabine Beck, Helmut Drexler, Bernhard Schieffer · 2006 · Atherosclerosis
8. Updates on the Treatment of Essential Hypertension: A Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Direct Renin Inhibitors
   Benjamin J. Powers, Laurence Greene, Lisa M. Balfe · 2011 · Journal of Managed Care Pharmacy
9. Suppressive Effects of Valsartan on Microalbuminuria and CRP in Patients with Metabolic Syndrome (Val-Mets)
   Tetsuro Shishido, Tsuneo Konta, Satoshi Nishiyama, Takehiko Miyashita, Takuya Miyamoto, Satoshi Takasaki, Joji Nitobe, Tetsu Watanabe, Yasuchika Takeishi, Isao Kubota · 2011 · Clinical and Experimental Hypertension
10. Angiotensin blockade in diabetic patients decreases insulin resistance‐associated low‐grade inflammation
    Maria G. Pavlatou, George P. Mastorakos, Alexandra Margeli, Evangelia E. Kouskouni, Nikolaοs Tentolouris, Nikos Katsilambros, George Panagiotis Chrousos, Ioannis Papassotiriou · 2010 · European Journal of Clinical Investigation
11. Higher IL-6 levels but not IL6 −174G>C or −572G>C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery
    Julie Sanders, Emma Hawe, David J. Brull, Christina Hubbart, Gordon D O Lowe, Ann Rumley, Steve Eric Humphries, Hugh Montgomery · 2008 · Atherosclerosis
12. Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease
    Natalia Pauli, Kamila Puchałowicz, Agnieszka Kuligowska, Andrzej Krzystolik, Violetta Dziedziejko, Krzysztof Safranow, Michał Rać, Dariusz Chlubek, Monika Ewa Rać · 2019 · Diagnostics
13. Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results
    Subodh Verma, Eva Lonn, Alykhan Nanji, Kevin F. Browne, Richard Ward, Annette Robertson, Heather E. Conradson, Kathy Hildebrand, Rollin Brant, Todd J. Anderson · 2009 · Canadian Journal of Cardiology
14. ACE-inhibitor therapy and survival among patients with multiorgan dysfunction syndrome (MODS) of cardiac and non-cardiac origin
    Hendrik Schmidt, Dirk Hoyer, Mathias Rauchhaus, Roland Prondzinsky, Ralf Hennen, Axel Schlitt, Justin Carter, Kuno Hottenrott, Ursula Müller‐Werdan, Karl Werdan et al. · 2009 · International Journal of Cardiology
15. Effects of 4 Weeks of Atorvastatin Administration on the Antiinflammatory Cytokine Interleukin-10 in Patients with Unstable Angina
    Jian‐Jun Li, Chun‐Hong Fang · 2005 · Clinical Chemistry
16. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control
    Helmy M. Siragy · 2008 · Current Hypertension Reports
17. The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats
    Polyana Lima Meireles Dalpiaz, Aline Zandonadi Lamas, Izabela Facco Caliman, Ana Raquel Santos Medeiros, G.R. Abreu, Margareth Ribeiro Moysés, Tadeu Uggere de Andrade, Márcio F.M. Alves, Adriana K. Carmona, Nazaré Souza Bissoli · 2013 · Brazilian Journal of Medical and Biological Research
18. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control.
    Thomas Unger, Anne Jakobsen, Jose Heroys, Ann Ralph, Tomas Rees, Michael Shaw · 2008 · PubMed Central
19. Combination inhibition of the renin–angiotensin system: is more better?
    Michelle W. Krause, Vivian Andrew Fonseca, Sudhir V. Shah · 2011 · Kidney International
20. ADMA, SDMA and L-Arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
    Aydın Kahraman, Emre Mutlu, Mustafa Aldağ · 2016 · Journal of Medical Biochemistry
21. Effect of Amlodipine + Candesartan on Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study)
    Junichi Yamaguchi, Nobuhisa Hagiwara, Hiroshi Ogawa, Ryo Koyanagi, Hiroshi Kasanuki, Atsushi Takagi, Fumiaki Mori, Michitaka Nagashima, Masahiro Yagi · 2010 · The American Journal of Cardiology
22. Effect of erythropoietin-stimulating agent on uremic inflammation
    Yuri Tanaka, Nobuhiko Joki, Hiroki Hase, Masaki Iwasaki, Masato Ikeda, Ryoichi Ando, Toshio Shinoda, Daijo Inaguma, Toshifumi Sakaguchi, Yasuhiro Komatsu et al. · 2012 · Journal of Inflammation
23. Lifestyle‐Induced Redox‐Sensitive Alterations: Cross‐Talk among the RAAS, Antioxidant/Inflammatory Status, and Hypertension
    Renáta Szabó, Denise Börzsei, Alexandra Hoffmann, Zelma Nadin Lesi, Rudolf Gesztelyi, Béla Juhász, Gábor J. Szebeni, Jasmin Osman, Judith Sebestyén, Arnold Nagy et al. · 2021 · Oxidative Medicine and Cellular Longevity
24. Effect of a common X-linked angiotensin II type 2-receptor gene polymorphism (−1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization
    Khaled Alfakih, Benjamin D. Brown, Richard A. Lawrance, P. Warburton, Azhar Maqbool, Kevin Walters, Nilesh J. Samani, Stephen G. Ball, Anthony J. Balmforth, Alistair S. Hall · 2007 · Atherosclerosis
25. Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis
    Akiyuki Uzawa, Masahiro Mori, Junko Taniguchi, Satoshi Kuwabara · 2014 · Clinical & Experimental Immunology
26. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
    Gilles Montalescot, H. Drexler, R. Gallo, Thomas A. Pearson, Martin Thoenes, Deepak L. Bhatt · 2009 · European Heart Journal
27. The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes
    David Z.I. Cherney, Heather N. Reich, James William Scholey, Denis Daneman, Farid H. Mahmud, Ronnie L. H. Har, Etienne B. Sochett · 2013 · Diabetologia
28. A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts
    Mojca Lunder, Miodrag Janić, Lovro Žiberna, Gorazd Drevenšek, Mišo Šabović · 2012 · Medical Science Monitor
29. Interplay between proteins and metabolic syndrome–A review
    Neetu Miglani, Kiran Bains · 2015 · Critical Reviews in Food Science and Nutrition
30. Inflammation in the genesis of hypertension and its complications the role of angiotensin II
    J. Li, Yvonne Döerffel, Berthold Hocher, Thomas Unger · 2007 · Nephrology Dialysis Transplantation
31. Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patientswith coronary artery disease
    Dimitris Tousoulis, Pantelis Kourtellaris, Charalambos A. Antoniades, Carmen Vasiliadou, Νικόλαος Παπαγεωργίου, Costas A. Tentolouris, Gerasimos Siasos, Elli Stefanadi, Christodoulos Stefanadis · 2007 · International Journal of Cardiology
32. Fat Cell‐Derived Modulators of Vascular Cell Pathophysiology: The List Keeps Growing
    Yonit Marcus, Naftali Stern · 2006 · Journal of the CardioMetabolic Syndrome
33. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?
    Sylvia Heeneman, Marjo M. P. C. Donners, Lili Bai, Mat J.A.P. Daemen · 2007 · Expert Review of Cardiovascular Therapy
34. Preoperative Treatment With an Angiotensin‐Converting Enzyme Inhibitor or an Angiotensin Receptor Blocker Has No Beneficial Effect on the Development of New‐Onset Atrial Fibrillation After Off‐Pump Coronary Artery Bypass Graft Surgery
    Ji‐Hyun Chin, Eun‐Ho Lee, Hyo Jung Son, Wook‐Jong Kim, Dae‐Kee Choi, Soo‐Kyoung Park, Ji‐Yeon Sim, In‐Cheol Choi, Kyung‐Don Hahm · 2011 · Clinical Cardiology
35. Inhibition of the renin–angiotensin system does not reduce platelet activity at rest or during stress in hypertension
    Jonas H. Schwieler, Thomas Kahan, N. Håkan Wallén, Jürg Nussberger, Paul Hjemdahl · 2013 · Journal of Hypertension
36. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension
    Stevo Julius, Brent M. Egan, Niko Kaciroti, Shawna D. Nesbitt, Andrew K. Chen · 2013 · Journal of Hypertension
37. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function
    Tsuyoshi Shiga, Hiroshi Kasanuki, Nobuhisa Hagiwara, Tetsuya Sumiyoshi, Takashi Honda, Kazuo Haze, Atsushi Takagi, Masatoshi Kawana, Hideki Origasa, Hiroshi Ogawa et al. · 2010 · Blood Pressure
38. Deletion of protein kinase B2 preserves cardiac function by blocking interleukin-6-mediated injury and restores blood pressure during angiotensin II/high-salt-diet-induced hypertension
    Shuai Yang, Dandan Chen, Fan Chen, Xinmei Zhao, Yubin Zhang, Zhe Li, Liang Jin, Yitao Xu, Daniel Sanchı́s, Junmei Ye · 2017 · Journal of Hypertension
39. Beneficial Effects of Angiotensin II Type 1 Receptor Blocker Antihypertensive Treatment on Inflammation Indices: The Effect of Smoking
    Stella-Maria Kyvelou, Gregory P. Vyssoulis, Eva A. Karpanou, Dionysios N. Adamopoulos, Theodoros P. Gialernios, Panagiota G. Pietri, Dennis V. Cokkinos, Christodoulos Stefanadis · 2007 · Journal of Clinical Hypertension
40. Modulation of TNF ‐α, interleukin‐6, and interleukin‐10 by nebivolol–valsartan and nebivolol–lisinopril polytherapy in SHR rats
    Diego Lezama‐Martínez, Jazmín Flores‐Monroy, Diana Ramírez‐Hernández, Garrido‐Farina German‐Isauro, Salvador Fonseca-Coronado, María Elena Hernández‐Campos · 2024 · Pharmacology Research & Perspectives
41. Interleukin‐10 negatively modulates extracellular signal‐regulated kinases 1 and 2 in aorta from hypertensive mouse induced by angiotensin II infusion
    Alecsander F. Bressan, Gisele A. Fonseca, Rita C. Tostes, Robert Clinton Webb, Victor V. Lima, Fernanda R. C. Giachini · 2018 · Fundamental and Clinical Pharmacology
42. Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice
    Jakub Gawryś, Karolina Gawryś, Ewa Szahidewicz-Krupska, Arkadiusz Derkacz, Jakub Mochol, Adrian Doroszko · 2018 · BioMed Research International
43. Psychoneuroimmunology of Stroke
    Robert Skinner, Rachel F. Georgiou, Peter Thornton, Nancy J. Rothwell · 2009 · Immunology and Allergy Clinics of North America
44. Psychoneuroimmunology of Stroke
    Robert Skinner, Rachel F. Georgiou, Peter Thornton, Nancy J. Rothwell · 2006 · Neurologic Clinics
45. Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial
    Martin Marinšek, Andreja Sinkovič · 2016 · BioMed Research International
46. Venthamarai chooranam, a polyherbal Siddha medicine, alleviates hypertension via AT 1 R and eNOS signaling pathway in 2K1C hypertensive rats
    Saravana Babu Chidambaram, Periyathambi Kalaivani, Vijayan Ranju, Sathiya Sekar, Chandrasekar Anbarasi, Mahadevan Mv, Vijayakumar Harivanzan, Adoor Gopalan Sunil, Sadagopan Thanikachalam · 2014 · Experimental Biology and Medicine
47. Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure?
    Ana Carolina Alba, Diego Delgado · 2009 · Expert Review of Cardiovascular Therapy
48. Ang II-Induced Hypertension Exacerbates the Pathogenesis of Tuberculosis
    Soo‐Na Cho, Jiae Choi, Junghwan Lee, Sang‐Hun Son, Seong-Ahn Lee, Tam-Doan Nguyen, Song‐Yi Choi, Chang‐Hwa Song · 2021 · Cells
49. Mechanisms of Benefit of Angiotensin Receptor Blockers in Coronary Atherosclerosis
    Christopher S. Vaccari, Stamatios Lerakis, Ramadan Hammoud, Bobby V. Khan · 2008 · The American Journal of the Medical Sciences
50. Effects of Valsartan on Inflammatory and Oxidative Stress Markers in Hypertensive, Hyperglycemic Patients: An Open-Label, Prospective Study
    Koji Kuboki, Kaoru Iso, Eiichi Murakami, Seiko Abe, E Araki, Hajime Ueshiba, Gen Yoshino · 2007 · Current Therapeutic Research
51. The effects of telmisartan on the nuclear factor of activated T lymphocytes signalling pathway in hypertensive patients
    Shasha Huang, Si-Li He, Yuan‐Ming Zhang · 2016 · Journal of the Renin-Angiotensin-Aldosterone System
52. The Pleiotropic Effects of Antihypertensive Agents: Do They Account for Additional Cardiovascular Benefit Beyond BP Reduction?
    HOWARD S. WEINTRAUB, JAN N. BASILE · 2008 · Southern Medical Journal
53. Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2
    Johannes Ruef, Michael Browatzki, Caroline AH Pfeiffer, Joachim Schmidt, Roger Kranzhöfer · 2007 · Vascular Medicine
54. A primer on the immune system in the pathogenesis and treatment of atherosclerosis
    Dolf Segers, Hector Garcia-Garcia, Caroline Cheng, Rini de Crom, Rob Krams, Jolanda J. Wentzel, Anton F. W. van der Steen, Patrick W.J.C. Serruys, Pieter J. M. Leenen, Jon D. Laman · 2008 · EuroIntervention
55. Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study
    Dorien M. C. F. Sluijsmans, Daphne C. Rohrich, Călin D. Popa, Bart J. F. van den Bemt · 2021 · Journal of Clinical Medicine
56. Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
    Zhe Liu, Qin Wang, Na Li, Chunyu Xu, Yunpu Li, Jun F. Zhou, Liu Liu, Haijing Zhang, Yang Mo, Feng Han et al. · 2023 · Frontiers in Public Health
57. Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment
    Kailash Prasad · 2024 · International Journal of Angiology
58. Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets.
    S. Demyanets, K. Huber, J. Wojta · 2012 · Vascular pharmacology
59. Approach to a Successful Selection of Antihypertensive Drugs for the Patient With Atherosclerosis
    Manuel Velasco, Edward Rojas, Valmore Bermúdez · 2012 · American Journal of Therapeutics
60. Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
    Sherry-Ann N. Brown, Svetlana Zaharova, Peter Mason, Jonathan Thompson, Bicky Thapa, David C. Ishizawar, Erin Wilkes, Gulrayz Ahmed, Jason Rubenstein, Joyce Sanchez et al. · 2020 · Frontiers in Cardiovascular Medicine
61. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND)
    Klaus Georg Parhofer, Kåre I. Birkeland, Ralph Anthony DeFronzo, Stefano Del Prato, Amitabha Bhaumik, Agata Ptaszynska · 2009 · International Journal of Clinical Practice
62. Metabolic Syndrome and Heart Failure
    Tina Kaur Thethi, Christina Bratcher, Vivian Andrew Fonseca · 2006 · Heart Failure Clinics
63. First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents
    Stefan Peters, Boris B. Behnisch, Torsten Heilmann, Christian Richter · 2009 · Journal of the Renin-Angiotensin-Aldosterone System
64. Angiotensin System Modulations in Spontaneously Hypertensive Rats and Consequences on Erythrocyte Properties; Action of MLN-4760 and Zofenopril
    Tomáš Jasenovec, Dominika Radošinská, Marta Kollárová, Peter Bališ, Ezgi Dayar, Iveta Bernátová, Štefan Zórad, Norbert Vrbjar, Sona Cacanyova, Jana Radošinská · 2021 · Biomedicines
65. Matrix metalloproteinases in thoracic aortic aneurysm disease
    Donald M. Botta, John Alex Elefteriades · 2006 · International Journal of Angiology
66. Vascular inflammation
    Valentı́n Fuster, Javier Sanz · 2007 · Journal of the American Society of Hypertension
67. Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise
    Annabella Braschi · 2019 · American Journal of Cardiovascular Drugs
68. Irbesartan: a review of its use alone and in combination with hydrochlorothiazide
    Claudio Borghi, Sibel Ertek, Arrigo F.G. Cicero · 2006 · Therapy
69. Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria
    Pim van der Harst, Folkert Wouter Asselbergs, Hans L. Hillege, Adriaan A. Voors, Dirk Jan van Veldhuisen, Wiek H. van Gilst · 2008 · The American Journal of Cardiology
70. Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan
    Thomas Unger · 2012 · ISRN Vascular Medicine
71. Alterations in Angiotensin Converting Enzyme During Rodent Aortic Aneurysm Formation
    Matthew Jeremiah Eagleton, Brenda S. Cho, Erin M. Lynch, Karen J. Roelofs, Derek T. Woodrum, James C. Stanley, Gilbert R. Upchurch · 2005 · Journal of Surgical Research
72. The Relationship Between Myocardial Fibrosis in Hypertensive Patients With Preserved Ejection Fraction and the Severity of Systemic Inflammatory Status Is Mediated by Epicardial Adipose Tissue: A Multicenter Cohort Study
    Wanting “Lisa” Wang, Runze Zhu, Wenxian Wang, Yan Gao, Jie Liu, Liang Wu, Ximing Wang · 2025 · Journal of Clinical Hypertension
73. The “Rise–Peak–Fall” Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats
    Miodrag Janić, Mojca Lunder, Darko Černe, Janja Marc, Aleš Jerin, Milan Skitek, Gorazd Drevenšek, Mišo Šabović · 2016 · Journal of Cardiovascular Pharmacology
74. Effect of myrtus communis extract on serum cytokines in angiotensin dependent hypertensive rats
    Zatiye Ayça ÇEVİKELLİ YAKUT, Büşra Ertaş, Ali Şen, Göksel Şener · 2020 · Medicine Science | International Medical Journal
75. The AT1 Receptor Blocker Telmisartan Reduces Intestinal Mucus Thickness in Obese Mice
    Laura Nickel, Annika Sünderhauf, Elias Rawish, Ines Stölting, Stefanie Derer, Christoph Thorns, Urte Matschl, Alaa Othman, Christian Sina, Walter Raasch · 2022 · Frontiers in Pharmacology
76. Follow‐Up of Cardiovascular Risk Markers in Hypertensive Patients Treated With Irbesartan: Results of the i‐SEARCH Plus Registry
    Ulrich Tebbe, Peter Bramlage, Stephan Lüders, Alessandro Cuneo, Peter Sistig, F. de Haan, Roland Erich Schmieder, Michael Böhm, W. Dieter Paar, Jochen Schrader · 2010 · Journal of Clinical Hypertension
77. Review of OxLDL Driven Inflammatory Cell Activation
    Martins Obinna Ogugofor, Devyani Holmes, Steven P. Gieseg · 2025 · Current Atherosclerosis Reports
78. Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting
    W. C. M. Rosa, Alexandre Holthausen Campos, Valter C. Lima · 2010 · Brazilian Journal of Medical and Biological Research
79. Recomendaciones específicas para el manejo del paciente con síndrome metabólico
    L. Vigil Medina, Manuel L. Jiménez, Rafael García Carretero · 2007 · Hipertensión y Riesgo Vascular
80. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
    Maximilian Tscharre, Patricia Pia Wadowski, Constantin Weikert, Joseph Pultar, Beate Eichelberger, Simon Panzer, Thomas Gremmel · 2020 · Cardiovascular Drugs and Therapy
81. Leukocyte subtypes, gelatinases, and their tissue inhibitors in a group of subjects with asymptomatic carotid atherosclerosis
    Gregorio Caimi, Caterina Urso, Salvatore Brucculeri, Corrado Amato, Rosalia Lo Presti, Melania Carlisi · 2022 · Clinical Hemorheology and Microcirculation
82. Inflammation and Hypertension
    Paolo Pauletto, Marcello Rattazzi · 2014 · Springer eBooks
83. Immunomodulation and its effector mechanisms in atherosclerosis
    Charlotta Hjerpe · 2007 · Figshare
84. Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome
    Thomas Bertsch, Tim Sueselbeck, Christian Wolpert, Ursula Hoffmann, Jens J. Kaden, Karl Konstantin Haase, Martin M. Borggrefe, Martina Brueckmann · 2005 · Clinical Chemistry and Laboratory Medicine (CCLM)
85. Beyond Blood Pressure
    Henning Morawietz · 2005 · Hypertension
86. Inhibitory effects of telmisartan on culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4 + T lymphocytes from Xinjiang Kazakh patients with hypertension
    Shasha Huang, Qiubing Zhang, Qingyan Yuan, Si-Li He, Yuan‐Ming Zhang · 2016 · Journal of the Renin-Angiotensin-Aldosterone System
87. Expression des Angiotensin converting enzyme (ACE) bei pulmonaler Hypertonie
    Annette Margarete Müller, M. Maas, U. Kozianka, Folker Ernst Franke · 2006 · Der Pathologe
88. The Obesity Epidemic and Kidney Disease: A Literature Review
    Veeraish Chauhan, Megha Vaid, Nishtha Chauhan, Akhil Parashar · 2012 · InTech eBooks
89. Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation
    Arnljot Tveit, Ingebjørg Seljeflot, Pål Smith, Harald Arnesen, Jesper Hastrup Svendsen · 2013 · Immunobiology
90. Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
    François Mach, Fabrizio Montecucco · 2009 · Current Chemical Biology
91. Inflammation and Atrial Fibrillation
    Anthony Sideris, Kostas Letsas · 2006 · Hospital chronicles/Hospital Chronicles
92. Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy
    Matteo Nardin, Monica Verdoia, Rocco Gioscia, Federica Negro, Giuseppe De Luca · 2020 · Nutrition Metabolism and Cardiovascular Diseases
93. Recomendaciones específicas para el manejo del paciente con síndrome metabólico
    L. Vigil Medina, Manuel L. Jiménez, Rafael García Carretero · 2007 · Hipertensión
94. Effects of albuminuria‐lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials
    Taha Sen, Viktor Rotbain Curovic, Niels Jongs, Gozewijn Dirk Laverman, Adriaan Kooy, Frederik Persson, Peter R Rossing, Hiddo J.L. Heerspink · 2023 · Diabetes Obesity and Metabolism
95. Forum ekspertów The role of C-reactive protein as a cardiovascular risk predictor
    George Boguslawski, Carlos Alberto Labarrere · 2006
96. Efeitos do ramipril sobre a doença periodontal induzida experimentalmente em ratos
    Ana Paula Akashi · 2016
97. The renin-angiotensin system in healthy human platelets: expressed but inactive
    François Panosetti, François M. Cuenot, Damian S. Saint Auguste, Ana C. Martins Cavaco, Allancer Nunes, Philip H. J. Lu, Céline E. M. Magrini, Max Molot, Gabriel Sanglard, Rodi Günçü et al. · 2025 · Platelets
98. Molecular docking-guided experimental evaluation of Azilsartan gel as therapeutic potential in a rat burn model
    Hawkar Qadir Baiz, Aram Ismael Ibrahim, Hemn Hasan Othman, Pshtiwan Gharib Ali, Tavga Ahmed Aziz, Zheen Aorahman Ahmed · 2025 · Journal of the Renin-Angiotensin-Aldosterone System
99. Impact of angiotensin-converting-enzyme inhibitors on intracranial aneurysm endovascular treatment outcome
    Kornelia Maria Kliś, Paweł Brzegowy, Antoni Cierniak, Igor Szydłowski, Aleksandra Midro, Roger Marek Krzyżewski, Borys Maria Kwinta, Krzysztof Stachura, Tadeusz Jan Popiela, Jerzy Gąsowski · 2026 · Neuroradiology
100. Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
     Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic, Juan Jesús Carrero, Sidar Çöpür, Ann Marie Navar, Brendon Lange Neuen, Vlado Perkovic, Peter R Rossing, Nikolaus Marx et al. · 2026 · Nature Reviews Nephrology